Cargando…

Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection

BACKGROUND: It remains unclear what the antiviral therapy affects disease-free survival (DFS) and overall survival (OS) of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) at different tumor stages and baseline HBV DNA levels. In this study, we analyzed the association of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jian-Lin, Lin, Xiao-Jun, Zhou, Qian, Shi, Ming, Li, Sheng-Ping, Lao, Xiang-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799530/ https://www.ncbi.nlm.nih.gov/pubmed/26992891 http://dx.doi.org/10.1186/s40880-016-0089-z

Ejemplares similares

Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection
por: Lin, Yen-Po, et al.
Publicado: (2021)

Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis
por: Liu, Kai-Xuan, et al.
Publicado: (2021)

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma
por: Gong, Wen-Feng, et al.
Publicado: (2017)

HBV-DNA Load-Related Peritumoral Inflammation and ALBI Scores Predict HBV Associated Hepatocellular Carcinoma Prognosis after Curative Resection
por: Liao, Rui, et al.
Publicado: (2018)

Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative
por: Wang, Kai, et al.
Publicado: (2018)

Pimobendan Inhibits HBV Transcription and Replication by Suppressing HBV Promoters Activity
por: Yuan, Si-Yu, et al.
Publicado: (2022)

Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma
por: Dai, Xiao-Meng, et al.
Publicado: (2017)

Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis
por: Yuan, Peng, et al.
Publicado: (2016)

Corrigendum to “Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma”
por: Dai, Xiao-Meng, et al.
Publicado: (2017)

The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma
por: Yu, Liang-He, et al.
Publicado: (2011)

Clinical importance of TERT overexpression in hepatocellular carcinoma treated with curative surgical resection in HBV endemic area
por: Yu, Jeong Il, et al.
Publicado: (2017)

Prognostic value of preoperative computed tomography in HBV-related hepatocellular carcinoma patients after curative resection
por: Zhang, Wei, et al.
Publicado: (2019)

Comment on “Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis”
por: Mo, Han-Yue, et al.
Publicado: (2016)

Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy
por: Liu, Shousheng, et al.
Publicado: (2021)

The Infection Efficiency and Replication Ability of Circularized HBV DNA Optimized the Linear HBV DNA in Vitro and in Vivo
por: Li, Xiaosong, et al.
Publicado: (2015)

Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis
por: Xu, Mingxing, et al.
Publicado: (2019)

Response to: Comment on “Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis”
por: Yuan, Peng, et al.
Publicado: (2016)

Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma
por: Liu, Jian, et al.
Publicado: (2023)

Reduced HBV cccDNA and HBsAg in HBV-associated hepatocellular carcinoma tissues
por: Tantiwetrueangdet, Anchalee, et al.
Publicado: (2018)

HBV integrated genomic characterization revealed hepatocyte genomic alterations in HBV-related hepatocellular carcinomas
por: Yang, Ming, et al.
Publicado: (2020)

ATM and ATR Expression Potentiates HBV Replication and Contributes to Reactivation of HBV Infection upon DNA Damage
por: Kostyusheva, Anastasiya, et al.
Publicado: (2019)

Frequency of hepatic HBV-DNA in patients with cirrhosis and hepatocellular carcinoma: relation to serum HBV markers.
por: White, Y. S., et al.
Publicado: (1990)

In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma
por: Zheng, Ye, et al.
Publicado: (2022)

HBV replication is significantly reduced by IL-6
por: Kuo, Tzer-Min, et al.
Publicado: (2009)

An HBV-encoded miRNA activates innate immunity to restrict HBV replication
por: Zhao, Xiaoqing, et al.
Publicado: (2019)

HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion
por: Li, Lian, et al.
Publicado: (2019)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

HBV cccDNA: The Stumbling Block for Treatment of HBV Infection
por: Liu, Shousheng, et al.
Publicado: (2019)

HBV genome-enriched single cell sequencing revealed heterogeneity in HBV-driven hepatocellular carcinoma (HCC)
por: Wang, Wenhui, et al.
Publicado: (2022)

Enchanced levels of apolipoprotein M during HBV infection feedback suppresses HBV replication
por: Gu, Jin-Gang, et al.
Publicado: (2011)

Preoperative γ-glutamyl transpeptidase to platelet ratio (GPR) is an independent prognostic factor for HBV-related hepatocellular carcinoma after curative hepatic resection
por: Wang, Wan-Li, et al.
Publicado: (2016)

Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes
por: Lucifora, Julie, et al.
Publicado: (2018)

Establishment of stable cell lines in which the HBV genome replicates episomally for evaluation of antivirals
por: Sun, Suofeng, et al.
Publicado: (2018)

Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma
por: Zhao, Ling-Hao, et al.
Publicado: (2016)

SIRT2 Promotes HBV Transcription and Replication by Targeting Transcription Factor p53 to Increase the Activities of HBV Enhancers and Promoters
por: Wu, Dai-Qing, et al.
Publicado: (2022)

Antiviral therapy of chronic HBV infection in pregnancy
por: Nikolajuk-Stasiuk, Julita, et al.
Publicado: (2016)

T cell receptor repertoire profiling predicts the prognosis of HBV‐associated hepatocellular carcinoma
por: Lin, Kai‐Rong, et al.
Publicado: (2018)

HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma: A retrospective case–control study
por: Li, Zhonghu, et al.
Publicado: (2016)

Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure
por: Yoo, Joseph, et al.
Publicado: (2018)

Profile of HBV Integration in the Plasma DNA of Hepatocellular Carcinoma Patients
por: Li, Weiyang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r9bt4krh4ck8pe3118k9i10cma